Daiichi Sankyo to Aim for Early Market Penetration for Ranmark in Copromotion with AZ

Daiichi Sankyo plans to aim for early stage market penetration for the anti-RANKL antibody Ranmark (recombinant denosumab) through copromotion with AstraZeneca K.K. (AZ), which boasts a strong presence in the cancer field. The company will target new patients and those...read more